Inside Amylyx's headquarters in Cambridge, MA (courtesy Amylyx/Kathy Wong for Endpoints News)

Amy­lyx read­ies for make-or-break PhI­II, look­ing to ad­dress un­cer­tain­ty over con­tro­ver­sial ALS drug

About a decade ago, David Buseck’s left foot first start­ed drag­ging dur­ing a race. He chalked it up to not be­ing much of a run­ner …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.